← Leaderboards
Derek Alan Wainwright
University Of Chicago
$7,505,477
Attributed
$8,885,773
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,885,773 · 7
By mechanism
R01$5,764,221 · 2
P50$1,439,303 · 1
R00$735,462 · 1
K02$688,392 · 1
K99$172,586 · 1
F32$85,809 · 1
Top collaborators
- Gary E Schiltz5 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Marcus R Clark$42,942,393
- Raymond Philip Roos$6,599,059
- Terrie Vasilopoulos$105,268
- Lixing Yang$2,608,948
- Peter Aidan Savage$14,017,592
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesGlioblastomaCellsImmunotherapyTumorFutureAffectMalignant Neoplasm Of BrainMediatingAdultKynurenineTryptophanDioxygenasesRegulatory T-LymphocyteInvestigationBaseIndoleamineT-LymphocyteImmunosuppressionImmune ResponseClinical TrialsDiagnosisMouse ModelGene Expression
Grant awards (31)
IDO1 and Immunotolerance in Glioblastoma$502,054
R01 · FY2025 · NS · contact PI
Extratumoral biological determinants that decrease survival in older adults with glioblastoma$385,000
R01 · FY2025 · NS · contact PI
IDO1 and Immunotolerance in Glioblastoma$487,318
R01 · FY2024 · NS · contact PI
Extratumoral biological determinants that decrease survival in older adults with glioblastoma$373,450
R01 · FY2024 · NS · contact PI
Aging, immunosenescence and glioblastoma$126,792
K02 · FY2024 · AG · contact PI
IDO1 and Immunotolerance in Glioblastoma$515,890
R01 · FY2023 · NS · contact PI
Extratumoral biological determinants that decrease survival in older adults with glioblastoma$385,000
R01 · FY2023 · NS · contact PI
Aging, immunosenescence and glioblastoma$126,792
K02 · FY2023 · AG · contact PI
IDO1 and Immunotolerance in Glioblastoma$628,320
R01 · FY2022 · NS · contact PI
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma$288,421
P50 · FY2022 · CA · contact PI
Aging, immunosenescence and glioblastoma$144,936
K02 · FY2022 · AG · contact PI
IDO1 and Immunotolerance in Glioblastoma$627,010
R01 · FY2021 · NS · contact PI
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma$237,852
P50 · FY2021 · CA · contact PI
Aging, immunosenescence and glioblastoma$144,936
K02 · FY2021 · AG · contact PI
IDO1 and Immunotolerance in Glioblastoma$406,136
R01 · FY2020 · NS · contact PI
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma$342,946
P50 · FY2020 · CA · contact PI
Aging, immunosenescence and glioblastoma$144,936
K02 · FY2020 · AG · contact PI
IDO1 and Immunotolerance in Glioblastoma$406,629
R01 · FY2019 · NS · contact PI
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma$314,529
P50 · FY2019 · CA · contact PI
IDO1 and Immunotolerance in Glioblastoma$40,902
R01 · FY2019 · NS · contact PI
IDO1 and Immunotolerance in Glioblastoma$336,225
R01 · FY2018 · NS · contact PI
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma$255,555
P50 · FY2018 · CA · contact PI
IDO1 and Immunotolerance in Glioblastoma$336,419
R01 · FY2017 · NS · contact PI
IDO1 and Immunotolerance in Glioblastoma$333,868
R01 · FY2016 · NS · contact PI
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma$241,269
R00 · FY2016 · NS · contact PI
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma$245,193
R00 · FY2015 · NS · contact PI
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma$249,000
R00 · FY2014 · NS · contact PI
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma$86,293
K99 · FY2014 · NS · contact PI
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma$86,293
K99 · FY2013 · NS · contact PI
The role of IDO and Th17 in an experimental mouse model of glioma$37,411
F32 · FY2012 · NS · contact PI
The role of IDO and Th17 in an experimental mouse model of glioma$48,398
F32 · FY2011 · NS · contact PI